MPR

Palsonify, an Oral Therapy for Acromegaly, Gets FDA Approval

The Food and Drug Administration (FDA) has approved Palsonify ™ (paltusotine) for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an ...
MPR

FDA Clears Eyeglass Lenses to Slow Myopia Progression in Children

The Food and Drug Administration (FDA) has cleared the Essilor Stellest eyeglass lenses to slow the progression of myopia, with or without astigmatism, in children aged 6 to 12 years at the initiation ...
MPR

Guidance Issued on Impact, Management of Potassium, Phosphorus in CKD

Potassium additives may be beneficial for patients at low risk for hyperkalemia, while phosphorus additives offer no health benefits.
MPR

Psilocybin-Assisted Therapy Aids Symptoms of Major Depressive Disorder

HealthDay News — Psilocybin-assisted therapy (PAT) shows long-term safety and efficacy for treating symptoms of major depressive disorder (MDD), according to a study published online September 4 in ...
MPR

Evkeeza Approval Expanded to Include Younger HoFH Patients

The Food and Drug Administration (FDA) has expanded the approval of Evkeeza ® (evinacumab-dgnb) to include children aged 1 year and older with homozygous familial hypercholesterolemia (HoFH).
MPR

Clinical Practice Guidelines Issued for Diabetes Distress

HealthDay News — The first clinical practice guidelines on assessment and management of diabetes distress among adults were presented at the annual meeting of the European Association for the Study of ...
MPR

MPR Weekly Dose Podcast #250

The CDC recommends changes to MMRV vaccine use; Trump administration claims acetaminophen linked to autism; first Barth syndrome treatment gets green light; gene therapy looks promising for Huntington ...
MPR

Wrist Cooling May Help Manage Vasomotor Symptoms

HealthDay News — Targeted wrist cooling may offer a safe approach for managing vasomotor symptoms, according to a study published online September 20 in Endocrinology and Diabetes.
MPR

FDA Removes REMS for Thyroid Cancer Drug Caprelsa

Since its approval, there have been no cases of torsades de pointes or unexplained sudden death among US patients treated with Caprelsa.
MPR

Acupuncture Beneficial for Chronic Low Back Pain in Older Adults

Significantly better change scores seen in Roland-Morris Disability Questionnaire at six and 12 months with acupuncture ...
MPR

Only 36.4% of US Adults Had No CVD Risk Factors in Recent Years

HealthDay News — During August 2021 to August 2023, only 36.4% of US adults had no cardiovascular disease (CVD) risk factors, according to a September data brief published by the National Center for ...
MPR

Trastuzumab Deruxtecan + Pertuzumab Under Review For First-Line HER2+ Metastatic Breast Cancer

Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu as a second-line therapy for HER2-positive metastatic breast ...